Literature DB >> 26123579

Association of hydrogen sulfide with alterations of monocyte chemokine receptors, CCR2 and CX3CR1 in patients with coronary artery disease.

Lin Gao1, Zuojun Xu, Zhaofang Yin, Kan Chen, Changqian Wang, Huili Zhang.   

Abstract

OBJECTIVES: Recent data in human and mice suggest that monocyte chemokine receptors CX3CR1 and CCR2 are involved in the pathogenesis of atherosclerosis. Our previous study showed that hydrogen sulfide, a novel gaseous mediator hampered the progression of atherosclerosis in fat-fed apoE(-/-) mice with downregulating CX3CR1 and CX3CL1 expressions. However, there is a paucity of information regarding the clinical association between endogenous H2S metabolism and alterations of monocyte chemokine receptors in patients with cardiovascular disease. Therefore, in this study, we investigated circulating monocyte heterogeneity with differential expressions of CCR2 and CX3CR1 and its relevance to plasma H2S level in patients with coronary artery disease (CAD).
METHODS: Sixty-three CAD patients with acute coronary syndrome (ACS, n = 46) or stable angina pectoris (SAP, n = 17) undergoing either percutaneous coronary intervention or coronary angiography and eleven non-CAD patients were enrolled in the study. Plasma levels of H2S as well as chemokines (CCL2 and CX3CL1) and expressions of CCR2 and CX3CR1 on peripheral monocytes were measured.
RESULTS: It was found that plasma H2S level was significantly reduced, whereas plasma CCL2 and CX3CL1 levels were substantially elevated in patients with ACS, as compared with patients with SAP or non-CAD patients. Furthermore, patients with ACS had significantly higher proportion of CD14(+)CCR2(+)CX3CR1(+) and CD14(+)CCR2(-)CX3CR1(+) monocytes but lower percentage of CD14(+)CCR2(+)CX3CR1(-) monocytes than SAP or non-CAD patients did. Lastly, plasma H2S level showed a significantly negative correlation with the proportion of CD14(+)CCR2(+)CX3CR1(+) monocytes, but not other monocyte subsets.
CONCLUSIONS: These data indicate that decreased endogenous H2S production may predispose stable CAD patients to rupture of vulnerable plaque and thus to ACS, probably in relation to circulating monocyte phenotypic transformation with differential expressions of CCR2 and CX3CR1.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26123579     DOI: 10.1007/s00011-015-0844-7

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  30 in total

Review 1.  Physiological implications of hydrogen sulfide: a whiff exploration that blossomed.

Authors:  Rui Wang
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

2.  Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques.

Authors:  Frank Tacke; David Alvarez; Theodore J Kaplan; Claudia Jakubzick; Rainer Spanbroek; Jaime Llodra; Alexandre Garin; Jianhua Liu; Matthias Mack; Nico van Rooijen; Sergio A Lira; Andreas J Habenicht; Gwendalyn J Randolph
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Role of hydrogen sulfide in cecal ligation and puncture-induced sepsis in the mouse.

Authors:  Huili Zhang; Liang Zhi; Philip K Moore; Madhav Bhatia
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-01-20       Impact factor: 5.464

4.  Association between circulating monocyte subsets and in-stent restenosis after coronary stent implantation in patients with ST-elevation myocardial infarction.

Authors:  Yong Liu; Toshio Imanishi; Hideyuki Ikejima; Hiroto Tsujioka; Yuichi Ozaki; Akio Kuroi; Keishi Okochi; Kohei Ishibashi; Takashi Tanimoto; Yasushi Ino; Hironori Kitabata; Takashi Akasaka
Journal:  Circ J       Date:  2010-10-07       Impact factor: 2.993

5.  CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease.

Authors:  Kyrill S Rogacev; Sarah Seiler; Adam M Zawada; Birgit Reichart; Esther Herath; Daniel Roth; Christof Ulrich; Danilo Fliser; Gunnar H Heine
Journal:  Eur Heart J       Date:  2010-10-12       Impact factor: 29.983

6.  Hydrogen sulphide: a novel physiological inhibitor of LDL atherogenic modification by HOCl.

Authors:  Hilde Laggner; Markus K Muellner; Sabine Schreier; Brigitte Sturm; Marcela Hermann; Markus Exner; Bernhard M K Gmeiner; Stylianos Kapiotis
Journal:  Free Radic Res       Date:  2007-07

7.  Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice.

Authors:  Christophe Combadière; Stéphane Potteaux; Mathieu Rodero; Tabassome Simon; Adeline Pezard; Bruno Esposito; Régine Merval; Amanda Proudfoot; Alain Tedgui; Ziad Mallat
Journal:  Circulation       Date:  2008-03-17       Impact factor: 29.690

8.  Protective effect of hydrogen sulfide on balloon injury-induced neointima hyperplasia in rat carotid arteries.

Authors:  Qing H Meng; Guangdong Yang; Wei Yang; Bo Jiang; Lingyun Wu; Rui Wang
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

9.  Effect of S-aspirin, a novel hydrogen-sulfide-releasing aspirin (ACS14), on atherosclerosis in apoE-deficient mice.

Authors:  Huili Zhang; Changfa Guo; Alian Zhang; Yuqi Fan; Ting Gu; Duojiao Wu; Anna Sparatore; Changqian Wang
Journal:  Eur J Pharmacol       Date:  2012-10-16       Impact factor: 4.432

10.  Hydrogen sulfide inhibits the development of atherosclerosis with suppressing CX3CR1 and CX3CL1 expression.

Authors:  Huili Zhang; Changfa Guo; Duojiao Wu; Alian Zhang; Ting Gu; Liansheng Wang; Changqian Wang
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

View more
  10 in total

Review 1.  Vascular biology of hydrogen sulfide.

Authors:  Nancy L Kanagy; Csaba Szabo; Andreas Papapetropoulos
Journal:  Am J Physiol Cell Physiol       Date:  2017-02-01       Impact factor: 4.249

2.  Hydrogen Sulfide and the Immune System.

Authors:  Peter Rose; Yi-Zhun Zhu; Philip K Moore
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Dermatoglyphs in Coronary Artery Disease Among Ningxia Population of North China.

Authors:  Hong Lu; Wenli Qian; Zhi Geng; Youjing Sheng; Haochen Yu; Zhanbing Ma; Zhenghao Huo
Journal:  J Clin Diagn Res       Date:  2015-12-01

Review 4.  Nitric oxide and hydrogen sulfide: the gasotransmitter paradigm of the vascular system.

Authors:  Giuseppe Cirino; Valentina Vellecco; Mariarosaria Bucci
Journal:  Br J Pharmacol       Date:  2017-05-16       Impact factor: 8.739

Review 5.  Hydrogen sulfide and vascular regulation - An update.

Authors:  Boyang Lv; Selena Chen; Chaoshu Tang; Hongfang Jin; Junbao Du; Yaqian Huang
Journal:  J Adv Res       Date:  2020-05-16       Impact factor: 10.479

Review 6.  The Impact of H2S on Obesity-Associated Metabolic Disturbances.

Authors:  Ferran Comas; José María Moreno-Navarrete
Journal:  Antioxidants (Basel)       Date:  2021-04-21

7.  Imbalance of Endogenous Hydrogen Sulfide and Homocysteine in Chronic Obstructive Pulmonary Disease Combined with Cardiovascular Disease.

Authors:  Yanjing He; Shaoyu Liu; Zhe Zhang; Chengcheng Liao; Fan Lin; Wanzhen Yao; Yahong Chen
Journal:  Front Pharmacol       Date:  2017-09-12       Impact factor: 5.810

8.  Hydrogen sulfide inhibits PCSK9 expression through the PI3K/Akt‑SREBP‑2 signaling pathway to influence lipid metabolism in HepG2 cells.

Authors:  Jun Xiao; Xue-Qin Bai; Ling Liao; Min Zhou; Juan Peng; Qiong Xiang; Zhong Ren; Hong-Yan Wen; Zhi-Sheng Jiang; Zhi-Han Tang; Mei-Mei Wang; Lu-Shan Liu
Journal:  Int J Mol Med       Date:  2019-03-01       Impact factor: 4.101

Review 9.  The Role of Hydrogen Sulfide on Cardiovascular Homeostasis: An Overview with Update on Immunomodulation.

Authors:  Li-Long Pan; Ming Qin; Xin-Hua Liu; Yi-Zhun Zhu
Journal:  Front Pharmacol       Date:  2017-09-26       Impact factor: 5.810

Review 10.  Hydrogen Sulfide (H2S)-Releasing Compounds: Therapeutic Potential in Cardiovascular Diseases.

Authors:  Lei Zhang; Yanan Wang; Yi Li; Lingli Li; Suowen Xu; Xiaojun Feng; Sheng Liu
Journal:  Front Pharmacol       Date:  2018-09-21       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.